<DOC>
	<DOCNO>NCT00540423</DOCNO>
	<brief_summary>This Phase II/III multicenter study comprise double-blind , follow open-label phase evaluate compare efficacy tolerability eltrombopag ( SB-497115-GR ) chronic ITP patient</brief_summary>
	<brief_title>Clinical Evaluation SB-497115-GR Chronic Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Inclusion criterion : Subjects eligible enrollment study must meet following criterion . At Screening ( Week 4 3 ) Diagnosed ITP least 6 month prior screen . Have platelet count &lt; 30,000/µL . Previously treat refractory relapse patient fail achieve platelet count &gt; =30,000/µL despite one prior therapy ( either H. pylorus eradication , corticosteroid , splenectomy , danazol immunosuppressive drug ) . ( Note : Previous H. pylorus eradication must complete least 3 month prior screen clearly ineffective ) . Previous treatment ITP splenectomy , rituximab , cyclophosphamide must complete Week 4 clearly ineffective . Subjects treat cyclosporine A , mycophenolate mofetil danazol must receive dose stable least 3 month prior screen . '' A complete blood count ( CBC ) within reference range , follow exception 1 . Hemoglobin : female &gt; =9g/dL male &gt; =10g/dL eligible inclusion hemorrhage present . 2 . Neutrophil count &gt; =1,500/µL ( 1.5x109/L ) require inclusion . The following clinical chemistry MUST NOT exceed 1.2 time normal reference range : creatinine , ALT , AST , total bilirubin alkaline phosphatase . Albumin must within 80 120 % normal range . Subject &gt; =20 year old . Female subject must either : nonchildbearing potential ( bilateral tubal ligation postmenopausal ) , childbearing potential negative pregnancy test agree use contraceptive method specify GSK List Highly Effective Methods Avoidance Pregnancy Hospitalization status : No restriction . Gender : No restriction . Subject sign dated write informed consent . At Randomization ( Week 0 ) Have platelet count &lt; 30,000/µL . Previous therapy ITP immunoglobulin ( IVIG antiD ) vincristine must complete least 2 week prior randomization platelet count must show clear downward trend last treatment immunoglobulin . Subjects treat corticosteroid azathioprine must receive dose stable least 4 week prior randomization . Prolongation prothrombin time activate partial thromboplastin time ( aPTT ) must exceed 1.2 time upper limit normal range history hypercoagulable state . ( Note : These parameter measure screen randomization . ) CBC clinical chemistry fulfill criterion screen . Reticulocyte count within reference range elevate case bleeding . ( Note : This parameter measure screening randomization . ) Exclusion criterion : Subjects meet follow criterion must enrol study . At Screening ( Week 4 3 ) Any severe medical condition ( cardiac , hepatic renal disorder ) chronic ITP . ( Note : `` '' Severe '' '' define &gt; =Grade 3 rule accord `` '' Classification Severity Adverse Experiences ( PAB/SD Notification No.80 , date 29 June 1992 ) ( Appendix X ) . ) History suspect confirm arterial venous thrombosis ( e.g. , myocardial infarction , deep vein thrombosis ) within last 1 year . History drug/alcohol abuse dependence within 1 year prior screen . Previous treatment SB497115GR . Suspected blood disorder ITP . Suspected platelet aggregation abnormality . Suspected cyclic thrombocytopenia Current history HIV infection hepatitis B virus hepatitis C virus infection . Current history malignancy ( Exception : Subjects history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible ) . Female subject nurse pregnant , may pregnant , contemplate pregnancy study period . Subjects deem unsuitable study investigator ( sub investigator ) . Subjects participate clinical trial present one previously participate clinical trial treat investigational product within last one month . '' At Randomization ( Week 0 ) Subject wish withdraw consent . Subject lose followup . Subject consume antiplatelet agent ( e.g. , ticlopidine aspirin ) , anticoagulant , nonsteroidal antiinflammatory drug ( NSAIDs ) 7days prior first dose study medication require medication study period . Subjects deem unsuitable study investigator ( sub investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>thrombopoietin ,</keyword>
	<keyword>immunosuppressive therapy ,</keyword>
	<keyword>eltrombopag ,</keyword>
	<keyword>idiopathic thrombocytopenic purpura ,</keyword>
	<keyword>blood platelet ,</keyword>
	<keyword>splenectomy</keyword>
</DOC>